Nemes Laszlo/iStock via Getty Images
- AbbVie (ABBV) said that its experimental T-cell engaging bispecific antibody Epkinly (epcoritamab) in combination with Revlimid (lenalidomide) led to better progression-free survival in large B-cell lymphoma patients who had failed on at least one prior therapy compared to those on a regimen
